Trends in excess mortality in follicular lymphoma at a population level

6533b829fe1ef96bd1289b97

RESEARCH PRODUCT

Trends in excess mortality in follicular lymphoma at a population level

Morgane Mounier Anne-sophie Woronoff Nadine Bossard Stéphanie Girard-boulanger Mylène Dandoit Jean Iwaz Rene-olivier Casasnovas Marc Maynadié Aurelien Belot Laurent Remontet Roch Giorgi Aurélie Herry

subject

Adult Male medicine.medical_specialty Adolescent Population level [SDV]Life Sciences [q-bio]Population Follicular lymphoma History 21st Century Young Adult 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine In patient Registries Age of Onset Stage (cooking)education Lymphoma Follicular Aged Neoplasm Staging Retrospective Studies Aged 80 and over Excess mortality education.field_of_study business.industry Hematology General Medicine History 20th Century Middle Aged medicine.disease 3. Good health Lymphoma Clinical trial Population Surveillance 030220 oncology & carcinogenesis Immunology Female France business 030215 immunology

description

Background Since the 1990s and since the development of humanised monoclonal antibodies in 1998, the treatment of non-Hodgkin lymphoma has undergone profound changes. Follicular lymphoma (FL) was the first to benefit from this treatment, and several clinical trials have shown a significant improvement in overall survival, but little information is available at a population level. Objective Our objective was to estimate changes in FL-specific mortality at a population level, with an appropriate methodology. Methods Two French retrospective population-based studies on FL were conducted, one from 1995 to 2004, in 1477 patients, and one from 1995 to 2010, in 451 patients. Trends in excess mortality rates (EMRs) according to age, sex, Ann Arbor stage and year of diagnosis were evaluated using the flexible model of Remontet et al. Results Trends in the EMR differed according to age at diagnosis and was higher in advanced stage (III, IV) in patients older than 65 yr. The EMR decreased linearly from 1995 to 2010. This decrease was more marked for advanced stages. Conclusion FL-specific mortality decreased over the years of diagnosis, and the difference according to the lymphoma stage diminished in more recent years. However, progress in the management of FL was not able to erase age-related differences.

year	journal	country	edition	language
2015-01-01

https://hal.archives-ouvertes.fr/hal-02025609